VistaGen Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VistaGen Therapeutics, Inc.
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
NASDAQ-listed company’s shares were reduced to penny stock after trial failures in 2019, but nasal spray PH10 offers glimmer of hope.
Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy for getting to market in the US and expanding its pipeline into new areas.
- Research, Analytical Equipment & Supplies
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- VistaStem Therapeutics, Inc.